Major depressive disorders pipeline: insights into leadership
Los Angeles, United States, Aug 25, 2021 (GLOBE NEWSWIRE) – Major Depressive Disorders Pipeline: Overview of Major Pharmaceutical Players, New Emerging Therapies, Clinical Trials and Future Perspectives | SearchInsight
The Major Depressive Disorders pipeline is evolving with new therapies as well as reoriented therapies in the pipeline, as well as a better understanding of the mechanisms of action.
DelveInsight’s ‘Overview of the major depressive disorder (MDD) pipeline‘ The report offers comprehensive coverage of the emerging therapeutic landscape at different stages of development, from preclinical to late stage, as well as dormant, inactive and abandoned therapeutic agents.
The Major Depressive Disorders Pipeline Reports provide a comprehensive picture of ongoing clinical trials, ongoing partnerships in the field, recent events in the space, and prospects for growth in the field of major depressive disorders.
Some of the highlights of the Major depressive disorders pipeline report:
- The Major Depressive Disorders Pipeline report provides a rich analysis of 75+ key players and 75+ key therapies.
- The Major Depressive Disorders pipeline includes therapies at different stages of the clinical phase, such as: Vraylar, PDC-1421, AV-101, AXS-05, Pramipexole, SAGE-217, LY03005, Seltorexant, PH10, PRAX-114, REL-1017, Caplyta, Lumateperone, and others, and many more are expected to enter the private label market over the next decade.
- Some of the key companies engaged in strengthening the major depressive disorders pipeline are Axsome Therapeutics, Luye Pharma, Sage Therapeutics, Chase Therapeutics, Minerva Biosciences, Relmada Therapeutics, Praxis Precision Medicines, Intra-Cellular Therapies, among others.
- In June 2021, Sage Therapeutics and Biogen announced the Phase III results of Zuranolone (WATERFALL study). The study met its primary endpoint, on day 15 zuranolone 50 mg showed a statistically significant and clinically significant reduction in depressive symptoms as measured by HAMD-17 (p = 0.0141) compared to placebo .
- In June 2021, Small Pharma announced the extension of its Phase I / IIa clinical trial for its flagship product, SPL026, an N, N-dimethyltryptamine (“DMT”) treatment for major depressive disorder.
Sample request to learn more about therapies set to capture maximum patients @ Emerging therapies and predictions for major depressive disorder
Major depressive disorder (MDD) is one of the most common psychiatric disorders that results in persistent sadness, loss of interest or pleasure, lack of energy, decreased appetite and sleep, and even suicide, disrupting daily activities and psychosocial functions. It is the main cause of the disease burden in high income countries.
For more information on emerging drugs, visit Major depressive disorder pipeline analysis
Drugs in the pipeline for major depressive disorder
|Vraylar||Allergan / Gedeon Richter||Phase III||Partial dopamine D2 receptor agonists||Oral|
|PDC-1421||Biolite inc.||Phase II||Plasma membrane transport protein norepinephrine inhibitors||Oral|
|AV-101||VistaGen Therapeutics||Phase II||NMDA receptor modulators||Oral|
|AXS-05||Axsome Therapeutics||Pre-registration||Adrenergic receptor antagonists||Oral|
|Pramipexole||Therapeutic chase||Phase II||Dopamine D2 receptor agonists||Oral|
|SAGE-217||Therapeutic sage||Phase III||GABA A receptor modulators||Oral|
|LY03005||Luye Pharma Group||Pre-registration||Serotonin uptake inhibitors||Oral|
|Seltorexant||Minerva Therapeutics||Phase III||Orexin type 2 receptor antagonists||Oral|
|PH10||VistaGen Therapeutics||Phase II||Cellular chemoreceptor stimulants||Intranasal|
|PRAX-114||Praxis Precision Medicines||Phase II / III||GABA modulators||Oral|
|REL-1017||Relmada Therapeutic||Phase III||NMDA receptor antagonists||Oral|
|Caplyta||Intracellular therapies||Phase III||Glutamate modulator||Oral|
Sample request to find out more @ Major Depressive Disorders Pipeline Analysis, Key Companies and Futuristic Trends
Therapeutic evaluation of major depressive disorder
The Major Depressive Disorders Pipeline report offers in-depth information of the active pipeline assets segmented by stage, product type, route of administration, molecule type, target, and mechanism of action.
By product type
- Phase I
- Phase II
- Phase III
By molecule type
- Bispecific antibody
- Small molecule
- Genetical therapy
By route of administration
By mechanism of action
- Dopamine D2 receptor agonist
- Serotonin 1A receptor agonists
- Glutamate modulator
- NMDA receptor modulators
- Adrenergic receptor antagonists
- GABA A receptor modulators
- Orexin type 2 receptor antagonists
- Dopamine D2 receptor
- Serotonin 1A receptor
- NMDA receiver
- Adrenergic receptor
- GABAA receiver
- Type 2 orexin receptor
Contact our sales manager for Informative business decisions, licensing services and consulting solutions
Scope of the report
Key players: Axsome Therapeutics, Luye Pharma, Sage Therapeutics, Chase Therapeutics, Minerva Biosciences, Relmada Therapeutics, Praxis Precision Medicines, Intra-Cellular Therapies, Gedeon Richter, Small Pharma, Clexio Biosciences, VistaGen Therapeutics, among others.
Key pipeline therapies for major depressive disorder: Vraylar, PDC-1421, AV-101, AXS-05, Pramipexole, SAGE-217, LY03005, Seltorexant, PH10, PRAX-114, REL-1017, Caplyta, Cariprazine, SPL026, CLE-100, among others.
To reach @ Major depressive disorders pipeline: new therapies and emerging technologies
|1||Presentation of the report|
|2||Major depressive disorder illness overview|
|3||Prospects for the Major Depressive Disorders Pipeline|
|5||Therapeutics for Clinical Major Depressive Disorder|
|6||Therapeutics for non-clinical major depressive disorder|
|7||Analysis of the therapeutic pipeline for major depressive disorder|
|8||Inactive Major Depressive Disorders Pipeline Products|
|ten||Methodology of the report|
Visit to learn more about what’s covered @ Major depressive disorders Emerging therapies, treatments and ongoing clinical trials
Complex Regional Pain Syndrome Market
DelveInsight’s’Complex Regional Pain Syndrome (CRPS) Market Overview, Epidemiology and Market Forecast-2030‘ report.
DelveInsight’s “Concussion Market Overview, Epidemiology and Market Forecast-2030” report.
Memory Disorders Market
DelveInsight’s “Memory Disorders – Market Overview, Epidemiology, and Market Forecast-2030” report.
Multiple Organ Dysfunction Syndrome Market
DelveInsight’s “Multiple Organ Dysfunction Syndrome Market Overview, Epidemiology and Market Forecast-2030” report.
Multiple Sclerosis Market
DelveInsight’s “Multiple Sclerosis Market Overview, Epidemiology and Market Forecast-2030” report.
Drug overdose market
DelveInsight’s ” Drug Overdose – Market Overview, Epidemiology and Market Forecast-2030” report.
DelveInsight’s’Narcolepsy Market Overview, Epidemiology and Market Forecast-2030‘ report..
Bipolar Disorder (Manic Depression) Market
DelveInsight’s’Bipolar Disorder (Manic Depression) – Market Overview, Epidemiology and Market Forecast-2030‘ report.
Postpartum Depression Market
DelveInsight report on “Postpartum Depression (PPD) – Market Overview, Epidemiology and Market Forecast – 2030”.
Treatment Resistant Depression Market
DelveInsight’s “Treatment Resistant Depression Market Overview, Epidemiology and Market Forecast-2030“report offer.
Mental health issues
Bipolar Depression Market
Depression and societal mental health
Schizophrenia market dynamics
DelveInsight is a leading business consulting and market research firm focused exclusively on the life sciences. It supports pharmaceutical companies by providing them with complete end-to-end solutions to improve their performance. Get hassle-free access to all healthcare and pharmaceutical market research reports through our subscription platform PharmaDelve.
For more information visit Pharmaceutical, medical and biotechnology news